Week in Review: $3.4 Billion Week for China Life Science Deals

Deals and Financings   Armo Biosciences, a Bay Area immuno-oncology company backed by China investors, will be acquired by Eli Lilly in a $1.6 billion transaction; Luye Pharma of Yantai will pay $538 million for rights to AstraZeneca's atypical anti-psychotic Seroquel in the UK , China and elsewhere; WeDoctor, a China online healthcare platform that is part of TenCent, closed a $500 million pre-IPO funding at a $5.5 billion valuation; WuXi AppTec completed a $345 million IPO of the company's main CRO business on the Shanghai stock exchange; CStone Pharma of Suzhou raised $260 million in a Series B financing, which the company claims is a record Series B round for any China biopharma; Unisound, a China artificial intelligence and voice recognition company, announced a $100 million C financing led by China Electronics Health Fund; Zhejiang BangEr Orthopedic Hospitals raised $47 Million in a Series C financing that was led by Qiming Venture Partners; Suzhou 's MabSpace Biosciences completed a $40 million B round to support its antibody programs; Ascletis Pharma of Hangzhou , a hepatitis C company, has the honor of being the first pre-revenue China biopharma to file for a Hong Kong IPO; Company News   Shandong Sinobioway Biomedicine, a Sinobioway subsidiary, announced plans to build a $471 million antibody CMO facility.    Stock Symbols: (NSDQ: ARMO) (NYSE: LLY) (HK: 2186) (NYSE: AZN) (HK: 0700) (SHA: 603259) (SHZ: 002581) Share this with colleagues: // //